Table 4.

Median SGCs at Week 6 and at Week 44 among patients who did and did not achieve clinical response, clinical remission, and mucosal healing endpoints in the PURSUIT studies.

Induction efficacy outcomes at Week 6	Week 6 SGC [µg/ml]		p-Value
	Achieved	Not Achieved
Clinical responsea	2.96 [n = 373]	1.55 [n = 320]	< 0.001
Mucosal healingb	3.14 [n = 315]	1.70 [n = 378]	< 0.001
Clinical remissionc	3.14 [n = 134]	2.13 [n = 559]	< 0.001
Maintenance efficacy outcomes	Week 44 SGC [µg/ml]		p-Value
	Achieved	Not achieved
Clinical responsea through Week 54	1.17 [n = 142]	0.83 [n = 57]	0.003
Mucosal healingb at Week 30 and Week 54	1.22 [n = 124]	0.83 [n = 75]	0.005
Clinical remissionc at Week 30 and Week 54	1.50 [n = 74]	0.87 [n = 125]	< 0.001

^aClinical response was defined as a decrease from baseline in the Mayo score ≥ 30% and ≥ 3 points, accompanied by either a rectal bleeding subscore of 0 or 1 or a decrease from baseline in the rectal bleeding subscore ≥ 1.

^bMucosal healing was defined as a Mayo endoscopy subscore of 0 or 1.

^cClinical remission was defined as a Mayo score ≤ 2 points, with no individual subscore > 1.

PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; SGC, serum golimumab concentration.